IPA (IMMUNOPRECISE ANTIBODIES LTD.) (NASDAQ: IPA), a biotherapeutics research and technology company driven by artificial intelligence, has acquired Carterra’s LSA® instrument platform. This high-throughput screening and characterization solution enhances IPA’s capabilities in antibody characterization through surface plasmon resonance, enabling advanced protein-protein interaction analyses such as kinetics, epitope binning, quantification, epitope mapping, and blocking/neutralization assays.
IPA (IMMUNOPRECISE ANTIBODIES LTD.) is dedicated to enhancing its capabilities as a contract research organization (CRO) by integrating advanced technology, especially in AI-driven drug design. The acquisition of Carterra’s LSA instrument reinforces IPA’s commitment to innovation and efficiency. The LSA platform’s high throughput and quick turnaround times with minimal sample volumes align perfectly with IPA’s expertise in high-performance skills, diversity, and data-driven drug discovery.
This strategic move not only accelerates in vitro characterizations for IPA’s customers and partners but also enriches LENS ai, IPA’s proprietary technology, with valuable datasets. Jennifer Bath, Ph.D., CEO and President of IPA, highlighted that this acquisition brings IPA closer to achieving the fastest and most cost-effective workflow in drug discovery.
Tim Germann, Chief Commercial Officer of Carterra, expressed excitement about revolutionizing drug discovery with IPA, emphasizing LSA’s role in generating vast amounts of data to train AI/ML engines rapidly.
About ImmunoPrecise Antibodies Ltd.: IPA is a biotherapeutic research and technology group with subsidiaries in North America and Europe, including Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) BV. The IPA Family leverages systems biology, multi-omics modeling, and complex AI systems to support antibody discovery technologies. Their services include the discovery, development, and licensing of therapeutic biologics to aid commercial partners in discovering and developing novel biologics against challenging targets.
